changes in protein profiles in bortezomib applied multiple myeloma ...

1.2.7. Treatment Strategy for MM
1.2.7.1. Bortezomib
Treatment strategy for MM is a very important and vital step for the patients,
because MM is currently still an incurable disease (Pandit, 2005; Dmoszyńska, 2008).
Bortezomib (Velcade ® , Millennium Pharmaceuticals Inc., and Johnson & Johnson
Pharmaceutical Research & Development, LLC) (LCLabs, USA) is the first of a new
class of anti-cancer agents known as proteasome inhibitor that was entered clinical
trials and firstly confirmed by the US Food and Drug Administration (FDA) and the
European Agency for the Evaluation of Medicinal Products (EMEA) for the treatment
of MM (Mateos and Miguel, 2007).
Bortezomib (previously known as PS-341, LDP-341, MLN341) is a dipeptide
boronic acid derivative, which specifically and reversibly inhibit proteasome activity
and triggers apoptosis in MM by binding the catalytic site of the 26S proteasome with
high affinity and specificity with the boron atom in its structure (Elliott and Ross, 2001;
Blade et al., 2003; Richardson et al., 2003; Voorhees et al., 2003; Adams and
Kauffman,2004; Chauhan et al., 2005). The chemical formula and molecular weight of
Bortezomib is C19H25BN4O4 and 384.24 g / mol respectively. The chemical structure of
Bortezomib is as follows (Figure 1.7).
Figure 1.7. Structure of Bortezomib
(Source: Blade et al., 2005)
19